Medunik Canada is pleased to announce that Health Canada has granted market authorization for Pheburane®

BLAINVILLE, QC (Canada) – January 27th, 2015 – Medunik Canada, a Canadian pharmaceutical company specialized in orphan drugs, is pleased to announce that Health Canada has issued a Notice of Compliance (NOC) for PHEBURANE® (a tasteless oral formulation of sodium phenylbutyrate), indicated as adjunctive therapy in the chronic management of urea cycle disorders (UCD), involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase. Canadians living with a urea cycle disorder will now have access to an approved tasteless medication for the treatment of this metabolic disease.

Read more

Medunik Canada announces Health Canada Priority Review of PHEBURANE® indicated for the treatment of Urea Cycle Disorders (UCD)

BLAINVILLE, QC (Canada) – September 24th, 2014 – Medunik Canada, a Canadian pharmaceutical company specialized in orphan drugs, announces that PHEBURANE® (a tasteless oral formulation of sodium phenylbutyrate), indicated as adjunctive therapy in the chronic management of Urea Cycle Disorders (UCD), was granted a Priority Review Status by Health Canada. This treatment will provide Canadians living with a urea cycle disorder access to a lower-cost alternative solution for the treatment of this metabolic disease.

Read more

Medunik Canada and Lucane Pharma conclude an exclusive licence and collaboration agreement

Blainville, Quebec (Canada) – December 4, 2013 - Medunik Canada, a pharmaceutical company specialized in orphan drugs and Lucane Pharma, a French niche pharmaceutical company, announced the conclusion of an exclusive collaboration agreement. Through this agreement, Medunik Canada receives the exclusive Canadian rights to market and distribute a new therapeutic option for patients suffering from Urea Cycle Disorders (UCD), a group of rare diseases involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate sythetase. This therapeutic option is taste-free, which facilitates medication and favours compliance to treatment.

Read more

Medunik Canada contributes $25,000 to the Wabano Mamawi Aboriginal Health Care Center

September 6, 2012 - On the occasion of a fundraising gala recently held in Ottawa, Medunik Canada announced a $25,000 contribution to support the expansion of the Wabano Mamawi Centre of Excellence in Aboriginal health care located in Vanier.

Read more

Medunik Canada Concludes a Strategic Collaboration Agreement with QOL Medical

On November 29, 2011, Medunik Canada has announced the conclusion of a strategic collaboration agreement with QOL Medical LLC. Under this agreement, Medunik Canada will work at optimizing the introduction and distribution of orphan drugs on the Canadian market, including the regulatory approval strategy and post-approval activities for two therapeutic options: Congenital Sucrase-Isomaltase Deficiency (CSID) and esophageal varices.

Read more